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LDL-C reduction of $17.12. In comparison, the costs 
per percent LDL-C reduction for equipotent strengths of
other statins were ﬂuvastatin 80mg at $17.93, simvas-
tatin 20mg at $36.84, pravastatin 40mg at $37.66 and
lovastatin 40mg at $47.29. Acquisition costs per unit for
these agents were $1.78, $1.72, $3.53, $3.51 and $4.02,
respectively. CONCLUSION: Acquisition cost is one
component in evaluating cost of therapy. However, in this
analysis, among equipotent agents, the agent with the
lowest acquisition cost was not the most cost effective.
Attempts to quantify cost effectiveness should be made
when reviewing the statin class.
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OBJECTIVES: Estimate the cost-effectiveness ratio in
France of treating high vascular risk patients with sim-
vastatin. METHODS: Data on efﬁcacy and resources
consumed were extracted from the published results of
the MRC/BHF Heart Protection Study (HPS) performed
in UK. HPS compared the occurrence of total and CHD
deaths, major vascular events (MVE), and major coro-
nary events (MCE) in more than 20,000 patients with
high vascular risk (patients with diabetes, history of
stroke or other cerebrovascular disease, peripheral arter-
ial disease, or with CHD). Patients were randomly
assigned to receive simvastatin or placebo and followed
at least for ﬁve years. The cost-effectiveness analysis was
performed using French unit costs. The survival beneﬁt
over the study period was estimated from the HPS results.
Direct costs included the extra costs of simvastatin and
the beneﬁt associated with avoided vascular events. Indi-
rect costs were not considered. Costs and beneﬁt were
discounted at 5%. RESULTS: All-cause mortality was
reduced by 13% (RR = 0.87, p = 0.0003). There was a
discounted survival beneﬁt of 0.040 year per included
patient. There were highly signiﬁcant reductions of about
one quarter in the risk of ﬁrst event rate of MVE (RR =
0.76, p < 0.0001) and of MCE (RR = 0.73, p = 0.0001).
The absolute value of the percentage of avoided event
during the 5-year period in the simvastatin group was
5.4% for any major vascular event, 2,1% for non fatal
MI, 1.3% for non fatal stroke, 2.4 % for revascularisa-
tion, 1.2% for fatal MI and 0.2% for fatal stroke. The
discounted extra cost of simvastatin was estimated at
€1994 ($1 = €1) taking into account the statins used in
the placebo group. This cost was reduced to €1031 by
considering the direct cost associated with avoided vas-
cular events. Cost-effectiveness ratio was then estimated
at €23,678 per life year gained (€22,000 to €50,000 
in the different subcategories of patients, ratios well
accepted as being cost-effective). CONCLUSIONS: Treat-
ment with simvastatin in different subcategories of
patients with high vascular risk is cost-effective in the
French setting.
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OBJECTIVES: Studies examining costs following
myocardial infarction (MI) have been limited by short
follow-up, small sample sizes, restricted patient popula-
tions, or failure to include hospital, physician, or market
characteristics. In a national sample with extensive sup-
plemental data, we sought to identify the baseline factors
predicting higher costs in the year following MI.
METHODS: Elderly acute MI patients totaling 84,373
(90% white, 49% female) in the Cooperative Cardiovas-
cular Project were linked to Medicare Part A claims, AHA
Hospital Surveys, the CMS directory of physician spe-
cialties, and the CMS Hospital Wage Index File. Medicare
charges were converted to costs using institutional cost to
charge ratios. Associations with admission episode and
one-year log-transformed costs were assessed by regres-
sion analysis with robust standard errors. RESULTS:
Mean cost was $12,956 (median $8,833) for the admis-
sion episode and $19,597 (median $13,583) at one year.
Patient characteristics accounted for 11% of the admis-
sion and one-year cost variation. Patient variables most
highly associated with one-year costs included anterior
MI, CHF, COPD, renal insufﬁciency, diabetes, and shock.
Older age (age 80 years) was most strongly associated
with lower costs. After adding hospital, physician, and
market variables, the models explained 22% of admission
and 17% of the one-year cost variation. Teaching hospi-
tals and care by a cardiologist were both associated with
higher one-year costs. While patient death was associated
with lower admission episode costs, death after the initial
episode was associated with higher one-year costs. CON-
CLUSION: In models examining the baseline predictors
of one-year costs following MI, patient characteristics
account for approximately twice the cost variation
accounted for by other baseline variables.
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OBJECTIVES: The study aimed at performing an eco-
nomic analysis in an American setting of the use of tran-
dolapril in postinfarction patients with left ventricular
dysfunction, based on the TRACE trial’s individual 
data. METHODS: The TRACE study was a prospective
placebo-controlled clinical trial designed to determine the
long-term effect of trandolapril in postinfarction patients
with left ventricular dysfunction. From 1992 to 1995,
1749 patients were followed. Our analysis was differen-
tial and was conducted from a Payer and a Medicare Per-
spectives in an American setting. Unit costs were attached
to uses of resources. Mean costs per Diagnosis Related
Groups (DRGs) enabled to value hospital stays for car-
diovascular events. Costs of treatments were obtained by
multiplying the duration of exposure by daily tariffs. The
cost analysis included a longitudinal analysis and multi-
variate regressions to identify cost drivers. The CE analy-
sis consisted in the estimation of the additional cost per
life-saved of treating patients with trandolapril. Uncer-
tainty surrounding the estimate of the CE ratio was taken
into account through a bootstrap analysis. RESULTS:
The mean costs of treatment with trandolapril reached
US$550 in the Payer Perspective. It was over compensated
by ﬁnancial savings in hospitalisations (US$-1308). The
total medical cost was lower (not signiﬁcantly) in the
trandolapril arm, with US$9607 versus US$9953. There
was a trend towards an increase in the cost differential in
favor of trandolapril on the long run. Main cost drivers
were diabetes (OR: 1.88; 95% CI: 1.4,2.5) and nitrate
use (OR: 1.67; 95% CI: 1.3,2.1) at inclusion. Among
5000 resamples of cost and mortality differentials, tran-
dolapril was respectively cost-effective and cost-saving in
33.3% and 66.7% of the cases. The CE analysis provided
similar results in the Medicare perspective. CONCLU-
SIONS: These results obtained in an American setting
could be considered as highly cost effective.
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OBJECTIVES: Anemia is known to affect clinical and
physiological outcomes in heart failure (HF) patients. We
investigate how changing hemoglobin levels inﬂuence
hospital length of stay (LOS) in HF patients across mul-
tiple hospitalizations. Methodological obstacles in apply-
ing 2-stage least squares (2SLS) panel data methods in
administrative data are also discussed. METHODS: A
panel dataset was assembled from claims data represent-
ing 1363 patients with 2 or more HF inpatient stays 
in 21 hospitals nationwide during the 1-year period,
October 1, 2000 through September 30, 2001. LOS is
modeled as a function of hemoglobin level, patient demo-
graphics, procedures performed during hospitalization
and hospital characteristics. To address endogeneity of
hemoglobin and LOS, hemoglobin level is instrumented
for, using indicator variables for hematinic prescriptions
and deﬁciency anemia diagnoses. Encounter data are not
collected at equal intervals. Thus, a key methodological
hurdle is identifying the minimum interval between
encounters meeting assumptions of 2SLS-panel methods.
Validity of model speciﬁcations is explored. Between-
effects and ﬁxed-effects models are developed and com-
pared. RESULTS: For all hemoglobin levels, there is a
slight secular decrease in LOS in the second hospitaliza-
tion during the study period. However, patients experi-
encing the greatest decrease in LOS are those who move
from being anemic in their ﬁrst stay to having normal
hemoglobin levels in their second stay. Between-effects
models indicate that a 1% improvement in hemoglobin
level between patients is associated with a 0.5 % (p <
0.001) decrease in LOS versus the other patients, con-
trolling for other factors. Fixed-effects models show that
a 1% increase in individual hemoglobin level is associ-
ated with a 3.6% (p < 0.001) decrease in LOS for that
individual. CONCLUSIONS: Results suggest the impact
of hemoglobin levels on LOS is greater within individual
patients hospitalized for HF than between individual
patients. Findings must be conﬁrmed in randomized, con-
trolled trials.
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OBJECTIVES: The Heart Outcomes Prevention Evalua-
tion (HOPE) study showed signiﬁcant mortality and mor-
bidity beneﬁts associated with ramipril in high-risk
patients. Cardiac mortality was signiﬁcantly reduced
from 8.1% in placebo to 6.1% in ramipril (RR, 0.74; 
p < 0.001). The objective of this study is to contrast 
multiple cost-effectiveness (CE) scenarios of ramipril in
preventing CV events in high-risk patients. METHODS:
Applying retrospective decision analytic technique, CE
analysis from a payer perspective was conducted using
direct medical costs of clinical events from the literature
and efﬁcacy data from the HOPE study. Expected cost
was estimated using probabilities associated with fatal
and non-fatal myocardial infarction, stroke and other CV
events. CE analysis was conducted under three alternate
scenarios of within-trial analysis based on cost and
outcome during the trial period of 4.5 years, persistent
beneﬁt analysis based on the assumption of therapy being
discontinued beyond trial period and an extended beneﬁt
analysis assuming patients continued on therapy beyond
trial period. Based on life expectancy for a similar cohort
reported in the literature, persistent-beneﬁt of therapy
was assumed for a period of 11.6 years. Extended bene-
ﬁts were obtained by extrapolating within trial efﬁcacy
beyond the study duration. CE analysis was conducted to
